Tumor-Associated CD[163.sup.+] M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer

Background: Programmed death-ligand 1 (PD-L1) is a negative costimulatory molecule, and its main function is widely considered to be in the regulation of T cells. Tumor-associated macrophages (TAMs) are an important part of the tumor microenvironment, and they also play an important role in immunosu...

Full description

Saved in:
Bibliographic Details
Published in:Cancer management and research 2020-07, Vol.12, p.5831
Main Authors: Guo, Fan, Feng, Yang-chun, Zhao, Gang, Zhang, Ran, Cheng, Zhen-zhen, Kong, Wei-na, Wu, Hui-li, Xu, Bin, Lv, Xiang, Ma, Xiu-min
Format: Article
Language:English
Subjects:
Analysis
B cells
Cervical cancer
Health aspects
Immunohistochemistry
Immunotherapy
Infiltration (Hydrology)
Macrophages
Pembrolizumab
Squamous cell carcinoma
T cells
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Programmed death-ligand 1 (PD-L1) is a negative costimulatory molecule, and its main function is widely considered to be in the regulation of T cells. Tumor-associated macrophages (TAMs) are an important part of the tumor microenvironment, and they also play an important role in immunosuppression. However, the relationship between the expression of PD-L1 and TAMs in cervical carcinoma (CC) remains unclear. We detected the expression of PD-L1 and TAMs in tumor tissue to study the correlation between them. Methods: Immunohistochemical staining of PD-L1, CD68 (pan-macrophage), and CD163 (M2-like macrophage) was performed in 120 cases of cervical squamous cell carcinoma. Logistic regression analysis was used to evaluate the predictors related to positive PD-L1 expression. We also apply the Kaplan-Meier method to study the recurrence-free and overall survival rate of CC patients. Results: The increase in PD-L1 expression in tumor cells (TC) was significantly correlated with the increase in CD163 density (r=0.8550, p
ISSN:1179-1322
1179-1322
DOI:10.2147/CMAR.S257692